Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma

STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. To overcome these challenges, our group had previou...

Full description

Bibliographic Details
Main Authors: Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/2/248
_version_ 1797763674712047616
author Yung-Hsing Huang
Mohammad Reza Vakili
Ommoleila Molavi
Yuen Morrissey
Chengsheng Wu
Igor Paiva
Amir Hasan Soleimani
Forugh Sanaee
Afsaneh Lavasanifar
Raymond Lai
author_facet Yung-Hsing Huang
Mohammad Reza Vakili
Ommoleila Molavi
Yuen Morrissey
Chengsheng Wu
Igor Paiva
Amir Hasan Soleimani
Forugh Sanaee
Afsaneh Lavasanifar
Raymond Lai
author_sort Yung-Hsing Huang
collection DOAJ
description STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. To overcome these challenges, our group had previously packaged STAT3 inhibitors using a novel formulation of nanoparticles (NP) and found encouraging results. In this study, we aimed to further improve the pharmacologic properties of these NP by decorating them with monoclonal anti-CD38 antibodies. NP loaded with S3I-1757 (a STAT3 inhibitor), labeled as S3I-NP, were generated. S3I-NP decorated with anti-CD38 (labeled as CD38-S3I-NP) were found to have a similar nanoparticular size, drug encapsulation, and loading as S3I-NP. The release of S3I-1757 at 24 h was also similar between the two formulations. Using Cy5.5 labeling of the NP, we found that the decoration of anti-CD38 on these NP significantly increased the cellular uptake by two MM cell lines (<i>p</i> &lt; 0.001). Accordingly, CD38-S3I-NP showed a significantly lower inhibitory concentration at 50% (IC50) compared to S3I-NP in two IL6-stimulated MM cell lines (<i>p</i> &lt; 0.001). In a xenograft mouse model, CD38-S3I-NP significantly reduced the tumor size by 4-fold compared to S3I-NP on day 12 after drug administration (<i>p</i> = 0.006). The efficacy of CD38-S3I-NP in suppressing STAT3 phosphorylation in the xenografts was confirmed by using immunocytochemistry and Western blot analysis. In conclusion, our study suggests that the decoration of anti-CD38 on NP loaded with STAT3 inhibitors can further improve their therapeutic effects against MM.
first_indexed 2024-03-12T19:44:47Z
format Article
id doaj.art-f30164702de74221b3ce31da3ee1ec28
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-12T19:44:47Z
publishDate 2019-02-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-f30164702de74221b3ce31da3ee1ec282023-08-02T03:36:28ZengMDPI AGCancers2072-66942019-02-0111224810.3390/cancers11020248cancers11020248Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaYung-Hsing Huang0Mohammad Reza Vakili1Ommoleila Molavi2Yuen Morrissey3Chengsheng Wu4Igor Paiva5Amir Hasan Soleimani6Forugh Sanaee7Afsaneh Lavasanifar8Raymond Lai9Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, CanadaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, CanadaDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, CanadaDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, CanadaDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, CanadaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, CanadaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, CanadaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, CanadaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, CanadaDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, CanadaSTAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. To overcome these challenges, our group had previously packaged STAT3 inhibitors using a novel formulation of nanoparticles (NP) and found encouraging results. In this study, we aimed to further improve the pharmacologic properties of these NP by decorating them with monoclonal anti-CD38 antibodies. NP loaded with S3I-1757 (a STAT3 inhibitor), labeled as S3I-NP, were generated. S3I-NP decorated with anti-CD38 (labeled as CD38-S3I-NP) were found to have a similar nanoparticular size, drug encapsulation, and loading as S3I-NP. The release of S3I-1757 at 24 h was also similar between the two formulations. Using Cy5.5 labeling of the NP, we found that the decoration of anti-CD38 on these NP significantly increased the cellular uptake by two MM cell lines (<i>p</i> &lt; 0.001). Accordingly, CD38-S3I-NP showed a significantly lower inhibitory concentration at 50% (IC50) compared to S3I-NP in two IL6-stimulated MM cell lines (<i>p</i> &lt; 0.001). In a xenograft mouse model, CD38-S3I-NP significantly reduced the tumor size by 4-fold compared to S3I-NP on day 12 after drug administration (<i>p</i> = 0.006). The efficacy of CD38-S3I-NP in suppressing STAT3 phosphorylation in the xenografts was confirmed by using immunocytochemistry and Western blot analysis. In conclusion, our study suggests that the decoration of anti-CD38 on NP loaded with STAT3 inhibitors can further improve their therapeutic effects against MM.https://www.mdpi.com/2072-6694/11/2/248multiple myelomaSTAT3S3I-1757nanoparticleCD38
spellingShingle Yung-Hsing Huang
Mohammad Reza Vakili
Ommoleila Molavi
Yuen Morrissey
Chengsheng Wu
Igor Paiva
Amir Hasan Soleimani
Forugh Sanaee
Afsaneh Lavasanifar
Raymond Lai
Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
Cancers
multiple myeloma
STAT3
S3I-1757
nanoparticle
CD38
title Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
title_full Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
title_fullStr Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
title_full_unstemmed Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
title_short Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
title_sort decoration of anti cd38 on nanoparticles carrying a stat3 inhibitor can improve the therapeutic efficacy against myeloma
topic multiple myeloma
STAT3
S3I-1757
nanoparticle
CD38
url https://www.mdpi.com/2072-6694/11/2/248
work_keys_str_mv AT yunghsinghuang decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT mohammadrezavakili decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT ommoleilamolavi decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT yuenmorrissey decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT chengshengwu decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT igorpaiva decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT amirhasansoleimani decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT forughsanaee decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT afsanehlavasanifar decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma
AT raymondlai decorationofanticd38onnanoparticlescarryingastat3inhibitorcanimprovethetherapeuticefficacyagainstmyeloma